Literature DB >> 29521454

Permanent neonatal diabetes mellitus and neurological abnormalities due to a novel homozygous missense mutation in NEUROD1.

Huseyin Demirbilek1, Nihal Hatipoglu2, Ulku Gul2, Zeynep U Tatli2, Sian Ellard3, Sarah E Flanagan3, Elisa De Franco3, Selim Kurtoglu2.   

Abstract

The basic helix-loop-helix (bHLH) transcription factor, neuronal differentiation 1 (NEUROD1) (also known as BETA2) is involved in the development of neural elements and endocrine pancreas. Less than 10 reports of adult-onset non-insulin-dependent diabetes mellitus (NIDDM) due to heterozygous NEUROD1 mutations and 2 cases with permanent neonatal diabetes mellitus (PNDM) and neurological abnormalities due to homozygous NEUROD1 mutations have been published. A 13 year-old female was referred to endocrine department due to hyperglycemia. She was on insulin therapy following a diagnosis of neonatal diabetes mellitus (NDM) at the age of 9-weeks but missed regular follow-up. Parents are second cousin. There was a significant family history of adult onset NIDDM including patient's father. Auxological measurements were within normal ranges. On laboratory examination blood glucose was 33.2 mmol/L with undetectable c-peptide and glycosylated hemoglobin level of 8.9% (73.8 mmol/mol). She had developed difficulty in walking at the age of 4 years which had worsened over time. On further evaluation, a diagnosis of visual impairment, mental retardation, ataxic gait, retinitis pigmentosa and sensory-neural deafness were considered. Cranial magnetic resonance imaging revealed cerebellar hypoplasia. Molecular genetic analysis using targeted next generation sequencing detected a novel homozygous missense mutation, p.Ile150Asn(c.449T>A), in NEUROD1. Both parents and 2 unaffected siblings were heterozygous for the mutation. We report the third case of PNDM with neurological abnormalities caused by homozygous NEUROD1 mutation, the first caused by a missense mutation. Heterozygous carriers of the p.Ile150Asn mutation were either unaffected or diagnosed with diabetes in adulthood. It is currently unclear whether the NEUROD1 heterozygous mutation has contributed to diabetes development in these individuals.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990NEUROD1 mutation; cerebellar hypoplasia; deafness; neonatal diabetes; retinitis pigmentosa

Mesh:

Substances:

Year:  2018        PMID: 29521454     DOI: 10.1111/pedi.12669

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  7 in total

Review 1.  Genetic Dissection and Clinical Features of MODY6 (NEUROD1-MODY).

Authors:  Yukio Horikawa; Mayumi Enya
Journal:  Curr Diab Rep       Date:  2019-02-22       Impact factor: 4.810

2.  Diabetes Mellitus Diagnosed in Childhood and Adolescence With Negative Autoimmunity: Results of Genetic Investigation.

Authors:  Marilea Lezzi; Concetta Aloi; Alessandro Salina; Martina Fragola; Marta Bassi; Marina Francesca Strati; Giuseppe d'Annunzio; Nicola Minuto; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

Review 3.  Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling.

Authors:  Yosef Tsegaye Dabi; Sisay Teka Degechisa
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-11       Impact factor: 3.249

4.  miR-374a-5p: A New Target for Diagnosis and Drug Resistance Therapy in Gastric Cancer.

Authors:  Runbi Ji; Xu Zhang; Hongbing Gu; Jichun Ma; Xiangmei Wen; Jingdong Zhou; Hui Qian; Wenrong Xu; Jun Qian; Jiang Lin
Journal:  Mol Ther Nucleic Acids       Date:  2019-08-27       Impact factor: 8.886

5.  The first case of NEUROD1-MODY reported in Latin America.

Authors:  Gabriella de Medeiros Abreu; Roberta Magalhães Tarantino; Pedro Hernan Cabello; Verônica Marques Zembrzuski; Ana Carolina Proença da Fonseca; Melanie Rodacki; Lenita Zajdenverg; Mário Campos Junior
Journal:  Mol Genet Genomic Med       Date:  2019-10-02       Impact factor: 2.183

6.  Targeted sequencing identifies novel variants in common and rare MODY genes.

Authors:  Lucas S de Santana; Lilian A Caetano; Aline D Costa-Riquetto; Pedro C Franco; Renata P Dotto; André F Reis; Letícia S Weinert; Sandra P Silveiro; Marcio F Vendramini; Flaviene A do Prado; Giovanna C P Abrahão; Ana Gregória F P de Almeida; Maria da G Rodrigues Tavares; Wagner Rodrigo B Gonçalves; Augusto C Santomauro Junior; Bruno Halpern; Alexander A L Jorge; Marcia Nery; Milena G Teles
Journal:  Mol Genet Genomic Med       Date:  2019-10-08       Impact factor: 2.183

Review 7.  Gene Therapy for Pancreatic Diseases: Current Status.

Authors:  Kenya Kamimura; Takeshi Yokoo; Shuji Terai
Journal:  Int J Mol Sci       Date:  2018-10-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.